DK1537204T3 - Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller - Google Patents

Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller

Info

Publication number
DK1537204T3
DK1537204T3 DK03792414.9T DK03792414T DK1537204T3 DK 1537204 T3 DK1537204 T3 DK 1537204T3 DK 03792414 T DK03792414 T DK 03792414T DK 1537204 T3 DK1537204 T3 DK 1537204T3
Authority
DK
Denmark
Prior art keywords
hsp70
tumor cells
granzym
cell death
programmed cell
Prior art date
Application number
DK03792414.9T
Other languages
English (en)
Inventor
Gabriele Prof Dr Multhoff
Original Assignee
Gabriele Prof Dr Multhoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gabriele Prof Dr Multhoff filed Critical Gabriele Prof Dr Multhoff
Application granted granted Critical
Publication of DK1537204T3 publication Critical patent/DK1537204T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464476—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03792414.9T 2002-08-23 2003-08-22 Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller DK1537204T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018284 2002-08-23
PCT/EP2003/009341 WO2004018002A2 (en) 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells

Publications (1)

Publication Number Publication Date
DK1537204T3 true DK1537204T3 (da) 2010-06-07

Family

ID=31896833

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03792414.9T DK1537204T3 (da) 2002-08-23 2003-08-22 Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller

Country Status (13)

Country Link
US (1) US7722863B2 (da)
EP (1) EP1537204B1 (da)
JP (1) JP4699755B2 (da)
AT (1) ATE457349T1 (da)
AU (1) AU2003260452A1 (da)
CA (1) CA2535952A1 (da)
CY (1) CY1110005T1 (da)
DE (1) DE60331228D1 (da)
DK (1) DK1537204T3 (da)
ES (1) ES2340270T3 (da)
PT (1) PT1537204E (da)
SI (1) SI1537204T1 (da)
WO (1) WO2004018002A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100034772A1 (en) * 2006-11-14 2010-02-11 Ralf Dressel Compositions and methods for immunotherapy
KR101192724B1 (ko) 2010-02-04 2012-10-18 한국생명공학연구원 마이크로알엔에이의 발현을 조절하여 ｎｋ 세포를 활성화시키는 방법
BR112013003989B1 (pt) 2010-08-20 2020-11-24 Immunovative Therapies, Ltd. composição compreendendo células cd4+ th1/assassinas e método in vitro para destruir células cancerosas, células infectadas ou combinações das mesmas
WO2018005926A1 (en) 2016-07-01 2018-01-04 The General Hospital Corporation Granzyme b directed imaging and therapy
WO2019043170A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh POLY THERAPY BASED ON HSP70
CN115477705B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
CN115305238B (zh) * 2022-09-19 2023-11-17 杭州凤喆凰生物科技有限公司 一种提高自然杀伤细胞杀伤力的成分在自然杀伤细胞培养中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
EP1007723A4 (en) * 1997-08-18 2001-11-28 Blood Res Center METHOD OF USING GRANZYMES AND FIXING MOLECULES THEREOF FOR TREATING DISEASES CHARACTERIZED BY ABNORMAL APOPTOSIS
IL137871A0 (en) * 1998-02-27 2001-10-31 Boehringer Ingelheim Pharma Self-regulated apoptosis of inflammatory cells by gene therapy
DE19813759C1 (de) * 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
JP4832640B2 (ja) * 1998-03-27 2011-12-07 ガブリエル ミュルソフ Ｈｓｐ７０タンパク質の新規使用
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
ES2292587T3 (es) * 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
WO2001091798A2 (en) * 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
EP1319023B8 (en) * 2000-09-13 2009-07-15 multimmune GmbH An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
US7101977B2 (en) * 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins

Also Published As

Publication number Publication date
WO2004018002A2 (en) 2004-03-04
EP1537204A2 (en) 2005-06-08
CY1110005T1 (el) 2015-01-14
DE60331228D1 (de) 2010-03-25
EP1537204B1 (en) 2010-02-10
WO2004018002A3 (en) 2004-06-17
AU2003260452A1 (en) 2004-03-11
ES2340270T3 (es) 2010-06-01
US7722863B2 (en) 2010-05-25
JP4699755B2 (ja) 2011-06-15
PT1537204E (pt) 2010-05-05
ATE457349T1 (de) 2010-02-15
CA2535952A1 (en) 2004-03-04
AU2003260452A8 (en) 2004-03-11
US20060111285A1 (en) 2006-05-25
JP2006507810A (ja) 2006-03-09
SI1537204T1 (sl) 2010-06-30

Similar Documents

Publication Publication Date Title
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
BRPI0514176A (pt) inibidores de replicação de hcv
EA200870164A1 (ru) Лечение вирусного гепатита
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
NO20055209D0 (no) Peptabody for cancerbehandling
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
CY1110005T1 (el) Γρανζυμο β ως ενας επαγωγεας αποπτωσης κυτταρων ογκων εξαρτωμενος απο ενα hsp70/hsp70 πεπτιδιο
MX2010006211A (es) Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.
UY28313A1 (es) Nonadepsipeptidos acilados
UY29189A1 (es) Nonadepsipeptidos acilados ii
ATE433459T1 (de) Desoxo-nonadepsipeptide
UY28353A1 (es) Inhibidores del papilomavirus
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
ATE455789T1 (de) Substituierte nonadepsipeptide